VVRA-TM 003

VVRA-TM 003 is an investigational drug candidate under development by Vivera Biosciences (a division of Vivera Pharmaceuticals) for the treatment of central nervous system (CNS) disorders. The therapeutic is formulated utilizing Vivera's proprietary TABMELT sublingual drug delivery technology, which allows the active pharmaceutical ingredient to dissolve rapidly under the tongue. This sublingual route is designed to bypass gastrointestinal tract degradation and first-pass hepatic metabolism, potentially offering faster onset of action, improved bioavailability, and enhanced patient compliance compared to traditional oral dosage forms.